Nat Clin Pract Cardiovasc Med. 2006;3(6):290-291. A positive causal relationship between the concentration of LDL cholesterol and the future risk of cardiovascular events is one of the best-proven ...
Hosted on MSN
New pill shows 60 per cent LDL reduction in trials: Cardiologists break down if it reduces heart attack risk
High levels of low-density lipoprotein cholesterol (LDL-C) are a key risk factor for cardiovascular disease, which continues to be one of the leading causes of illness and death globally. LDL-C can ...
YouTube on MSNOpinion
A concise masterclass on cholesterol-lowering medications
A concise, high-yield guide to cholesterol-lowering therapies—statins, Zetia, PCSK9 inhibitors, bempedoic acid, berberine, ...
An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a positive start in an early clinical trial. Researchers running a Phase I ...
BOSTON -- A PCSK9 inhibitor contributed extra LDL cholesterol lowering as an early add-on to standard high-intensity statins in the acute period of ST-segment elevation MI (STEMI), the small ...
The ability of niacin to influence LDL-P is under active investigation and it appears that the beneficial effects of niacin extend beyond the traditional evaluation of the 'lipid profile.' Taken ...
A Prescription Drug User Fee Act target date of December 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License Application ...
Use of OTC dietary supplements is increasingly common, sometimes replacing guideline-recommended therapies. Rosuvastatin was associated with larger reductions in LDL-C compared with placebo, fish oil, ...
A high global mortality rate is associated with cardiovascular disease (CVD), particularly atherothrombotic ischaemic stroke and coronary heart disease. Therefore, it is necessary to reduce ...
Results from the V-INITIATE trial showed a substantial 60% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 in the inclisiran first group compared with a mere 7% ...
Lower may indeed be better, suggests a new analysis of the FOURIER trial addressing outcomes in patients whose LDL cholesterol was brought below 40 mg/dL. The findings, say investigators, support some ...
Add Yahoo as a preferred source to see more of our stories on Google. https://www.tipranks.com/news/the-fly/apellis-price-target-lowered-to-18-from-20-at-wedbush ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results